Exelixis
EXEL
#2073
Rank
HK$59.63 B
Marketcap
HK$209.06
Share price
-2.83%
Change (1 day)
25.22%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): HK$3.52 B

According to Exelixis's latest financial reports the company's current earnings (TTM) are HK$3.51 B. In 2023 the company made an earning of HK$2.00 B an increase over its 2022 earnings that were of HK$1.82 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) HK$3.52 B75.49%
2023 HK$2.00 B9.89%
2022 HK$1.82 B-20.33%
2021 HK$2.29 B124.82%
2020 HK$1.01 B-67.14%
2019 HK$3.10 B-11.94%
2018 HK$3.52 B185.09%
2017 HK$1.23 B-325.82%
2016 -HK$0.55 B-58.12%
2015 -HK$1.31 B-37.61%
2014 -HK$2.1 B9.75%
2013 -HK$1.91 B65.96%
2012 -HK$1.16 B-291.63%
2011 HK$0.60 B-195.59%
2010 -HK$0.63 B-42.17%
2009 -HK$1.09 B-18.98%
2008 -HK$1.35 B-6.99%
2007 -HK$1.45 B46.3%
2006 -HK$0.99 B33.25%
2005 -HK$0.74 B-30.92%
2004 -HK$1.07 B44.29%
2003 -HK$0.75 B12.86%
2002 -HK$0.66 B22.79%
2001 -HK$0.54 B60.14%
2000 -HK$0.34 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
HK$48.87 B 1,290.27%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$52.61 B 1,396.72%๐Ÿ‡ซ๐Ÿ‡ท France
HK$128.54 B 3,556.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$50.04 B-1,523.38%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$27.47 B 681.65%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$158.02 B 4,395.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$9.45 B-368.75%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$0.37 B-110.34%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$0.23 B-106.44%๐Ÿ‡บ๐Ÿ‡ธ USA